GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Stock Based Compensation

Elanix Biotechnologies AG (FRA:ELN) Stock Based Compensation : €0.00 Mil (TTM As of Dec. 2018)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Stock Based Compensation?

Elanix Biotechnologies AG's Stock Based Compensation for the six months ended in Dec. 2018 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2018 was €0.00 Mil.


Elanix Biotechnologies AG Stock Based Compensation Historical Data

The historical data trend for Elanix Biotechnologies AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Stock Based Compensation Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Elanix Biotechnologies AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.


Elanix Biotechnologies AG Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Elanix Biotechnologies AG (FRA:ELN) Business Description

Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines